{"protocolSection":{"identificationModule":{"nctId":"NCT01352845","orgStudyIdInfo":{"id":"B1971016"},"secondaryIdInfos":[{"id":"6108A1-2004","type":"OTHER","domain":"Alias Study Number"},{"id":"2009-014492-46","type":"EUDRACT_NUMBER"},{"id":"2009","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2009"}],"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.","officialTitle":"A Phase 3, Randomized, Placebo-controlled, Observer-blinded, Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered As A 3-dose Regimen In Healthy Young Adults Aged >=18 To <26 Years","acronym":"B1971016"},"statusModule":{"statusVerifiedDate":"2016-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-05"},"primaryCompletionDateStruct":{"date":"2015-02","type":"ACTUAL"},"completionDateStruct":{"date":"2015-02","type":"ACTUAL"},"studyFirstSubmitDate":"2011-05-11","studyFirstSubmitQcDate":"2011-05-11","studyFirstPostDateStruct":{"date":"2011-05-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-01-26","resultsFirstSubmitQcDate":"2016-01-26","resultsFirstPostDateStruct":{"date":"2016-02-23","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-01-26","lastUpdatePostDateStruct":{"date":"2016-02-23","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young adults. The study will also look at the safety of the new vaccine as well as how it is tolerated."},"conditionsModule":{"conditions":["Healthy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":3301,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"rLP2086","type":"EXPERIMENTAL","interventionNames":["Biological: rLP2086"]},{"label":"Control","type":"PLACEBO_COMPARATOR","description":"Steril normal saline solution","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"rLP2086","description":"0.5 mL dose, given at 0, 2 and 6 months","armGroupLabels":["rLP2086"]},{"type":"OTHER","name":"Placebo","description":"0.5 mL dose, given at 0, 2 and 6 months","armGroupLabels":["Control"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1","description":"Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point. This outcome measure was planned to be analyzed for Group 1 only.","timeFrame":"One month after third bivalent rLP2086 vaccination"},{"measure":"Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination","timeFrame":"Within 7 days after first vaccination"},{"measure":"Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Second Vaccination","timeFrame":"Within 7 days after second vaccination"},{"measure":"Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Third Vaccination","timeFrame":"Within 7 days after third vaccination"},{"measure":"Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination","timeFrame":"Within 7 days after first vaccination"},{"measure":"Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination","timeFrame":"Within 7 days after second vaccination"},{"measure":"Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination","timeFrame":"Within 7 days after third vaccination"},{"measure":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After First Vaccination","timeFrame":"Within 30 days after first vaccination"},{"measure":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination","timeFrame":"Within 30 days after second vaccination"},{"measure":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination","timeFrame":"Within 30 days after third vaccination"},{"measure":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination","timeFrame":"Within 30 days after any vaccination"},{"measure":"Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase","timeFrame":"From the first vaccination up to 1 month after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination","timeFrame":"Within 30 days after first vaccination"},{"measure":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination","timeFrame":"Within 30 days after second vaccination"},{"measure":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination","timeFrame":"Within 30 days after third vaccination"},{"measure":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination","timeFrame":"Within 30 days after any vaccination"},{"measure":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase","timeFrame":"From 1 month after third vaccination up to 6 months after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase","timeFrame":"From the first vaccination up to 1 month after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period","timeFrame":"From the first vaccination up to 6 month after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination","timeFrame":"Within 30 days after first vaccination"},{"measure":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination","timeFrame":"Within 30 days after second vaccination"},{"measure":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination","timeFrame":"Within 30 days after third vaccination"},{"measure":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination","timeFrame":"Within 30 days after any vaccination"},{"measure":"Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase","timeFrame":"From the first vaccination up to 1 month after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase","timeFrame":"From 1 month after third vaccination up to 6 months after the third vaccination"},{"measure":"Percentage of Participants Reporting at Least 1 Medically Attended Adverse Event Throughout the Study Period","timeFrame":"From the first vaccination up to 6 month after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination","timeFrame":"Within 30 days after first vaccination"},{"measure":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination","timeFrame":"Within 30 days after second vaccination"},{"measure":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination","timeFrame":"Within 30 days after third vaccination"},{"measure":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination","timeFrame":"Within 30 days after any vaccination"},{"measure":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase","timeFrame":"From the first vaccination up to 1 month after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase","timeFrame":"From 1 month after third vaccination up to 6 months after the third vaccination"},{"measure":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period","timeFrame":"From the first vaccination up to 6 month after the third vaccination the third vaccination"},{"measure":"Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After First Vaccination","timeFrame":"Within 30 minutes after first vaccination"},{"measure":"Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Second Vaccination","timeFrame":"Within 30 minutes after second vaccination"},{"measure":"Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Third Vaccination","timeFrame":"Within 30 minutes after third vaccination"},{"measure":"Number of Days Participants Missed School or Work Due to AE During the Vaccination Phase","timeFrame":"From the first vaccination up to 1 month after the third vaccination"}],"secondaryOutcomes":[{"measure":"Percentage of Participants With hSBA Titers >= Lower Limit of Quantification for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination: Group 1","timeFrame":"Before first vaccination, 1 month after third vaccination"},{"measure":"Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, >=1:128 for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1","timeFrame":"Before first vaccination, 1 month after third vaccination (Vac)"},{"measure":"hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1","timeFrame":"Before first vaccination, 1 month after third vaccination"},{"measure":"Percentage of Participants Achieving Composite hSBA Titer >=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Group 1","timeFrame":"Before vaccination 1, 1 Month after Vaccination 2"},{"measure":"Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination: Group 1","timeFrame":"One month after second Bivalent rLP2086 vaccination"},{"measure":"Percentage of Participants With hSBA Titers >=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1","timeFrame":"Before Vaccination (Vac) 1, 1 Month after Vac 2, 3"},{"measure":"Percentage of Participants With hSBA Titers >=1:4,>=1:8,>=1:16,>=1:32,>=1:64,>=1:128 for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1","description":"Results for PMB80\\[A22\\] 1:16, PMB2001\\[A56\\] 1:8, PMB2948\\[B24\\] 1:8 and PMB2707\\[B44\\] 1:8 are reported under secondary endpoint 'Percentage of Participants With hSBA Titers \\>=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1'.","timeFrame":"Before Vaccination (Vac) 1, 1 Month after Vac 2, 3"},{"measure":"hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1","timeFrame":"Before Vaccination (Vac) 1, 1 Month after Vac 2, 3"},{"measure":"Percentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination","timeFrame":"One month after third bivalent rLP2086 vaccination"},{"measure":"Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1","timeFrame":"One month after third bivalent rLP2086 vaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female subject aged \\>=18 and \\<26 years at the time of enrollment.\n2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.\n3. Negative urine pregnancy test for all female subjects.\n\nExclusion Criteria:\n\n1. Previous vaccination with any meningococcal serogroup B vaccine.\n2. Subjects who are scheduled to receive 1 or more doses of an HPV vaccine as part of a 3-dose series during the period between Visit 1 and 28 days after the second vaccination.\n3. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.\n4. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.\n5. Significant neurological disorder or history of seizure (excluding simple febrile seizure).\n6. Current chronic use of systemic antibiotics.\n7. Received any investigational vaccines, drugs, or devices within 28 days before administration of the first study vaccination.\n8. Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"25 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Coastal Clinical Research, Inc.","city":"Mobile","state":"Alabama","zip":"36608","country":"United States","geoPoint":{"lat":30.69436,"lon":-88.04305}},{"facility":"Clinical Research Advantage, Inc./Desert Clinical Research, LLC","city":"Mesa","state":"Arizona","zip":"85213","country":"United States","geoPoint":{"lat":33.42227,"lon":-111.82264}},{"facility":"Clinical Research Advantage, Inc./ Fiel Family and Sports Medicine, PC","city":"Tempe","state":"Arizona","zip":"85282","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"Clinical Research Advantage, Inc./ Fiel Family and Sports Medicine, PC","city":"Tempe","state":"Arizona","zip":"85283","country":"United States","geoPoint":{"lat":33.41477,"lon":-111.90931}},{"facility":"Anaheim Clinical Trials LLC","city":"Anaheim","state":"California","zip":"92801","country":"United States","geoPoint":{"lat":33.83529,"lon":-117.9145}},{"facility":"eStudySite","city":"La Mesa","state":"California","zip":"91942","country":"United States","geoPoint":{"lat":32.76783,"lon":-117.02308}},{"facility":"Benchmark Research","city":"Sacramento","state":"California","zip":"95822","country":"United States","geoPoint":{"lat":38.58157,"lon":-121.4944}},{"facility":"Broward Research Group","city":"Hollyood","state":"Florida","zip":"33024","country":"United States"},{"facility":"Altus Research Inc.","city":"Lake Worth","state":"Florida","zip":"33461","country":"United States","geoPoint":{"lat":26.61708,"lon":-80.07231}},{"facility":"Miami Research Associates","city":"South Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.7076,"lon":-80.29338}},{"facility":"Palm Beach Research Center","city":"West Palm Beach","state":"Florida","zip":"33409","country":"United States","geoPoint":{"lat":26.71534,"lon":-80.05337}},{"facility":"Johnson County Clin-Trials, Inc.","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"Benchmark Research","city":"Metairie","state":"Louisiana","zip":"70006","country":"United States","geoPoint":{"lat":29.98409,"lon":-90.15285}},{"facility":"Milford Emergency Associates, Inc.","city":"Milford","state":"Massachusetts","zip":"01757","country":"United States","geoPoint":{"lat":42.13982,"lon":-71.51617}},{"facility":"The Center for Pharmaceutical Research","city":"Kansas City","state":"Missouri","zip":"64114","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"Bellevue Urgent Care","city":"Bellevue","state":"Nebraska","zip":"68005","country":"United States","geoPoint":{"lat":41.13667,"lon":-95.89084}},{"facility":"Meridian Clinical Research","city":"Bellevue","state":"Nebraska","zip":"68005","country":"United States","geoPoint":{"lat":41.13667,"lon":-95.89084}},{"facility":"Pioneer Clinical Research, LLC","city":"Bellevue","state":"Nebraska","zip":"68005","country":"United States","geoPoint":{"lat":41.13667,"lon":-95.89084}},{"facility":"Meridian Clinical Research,","city":"Omaha","state":"Nebraska","zip":"68134","country":"United States","geoPoint":{"lat":41.25626,"lon":-95.94043}},{"facility":"Central New York Clinical Research","city":"Manlius","state":"New York","zip":"13104","country":"United States","geoPoint":{"lat":43.00201,"lon":-75.97686}},{"facility":"PMG Research of Raleigh, LLC","city":"Raleigh","state":"North Carolina","zip":"27609","country":"United States","geoPoint":{"lat":35.7721,"lon":-78.63861}},{"facility":"Community Research","city":"Cincinnati","state":"Ohio","zip":"45227","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"Rapid Medical Research, Inc.","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Rapid Medical Research","city":"Cleveland","state":"Ohio","zip":"44122","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"PEAK Research, LLC","city":"Upper Saint Clair","state":"Pennsylvania","zip":"15241","country":"United States","geoPoint":{"lat":40.3359,"lon":-80.08339}},{"facility":"Coastal Medical","city":"East Greenwich","state":"Rhode Island","zip":"02818","country":"United States","geoPoint":{"lat":41.66038,"lon":-71.45589}},{"facility":"Omega Medical Research","city":"Warwick","state":"Rhode Island","zip":"02886","country":"United States","geoPoint":{"lat":41.7001,"lon":-71.41617}},{"facility":"Coastal Carolina Research Center","city":"Mt. Pleasant","state":"South Carolina","zip":"29464","country":"United States","geoPoint":{"lat":32.79407,"lon":-79.86259}},{"facility":"Meridian Clinical Research","city":"Dakota Dunes","state":"South Dakota","zip":"57049","country":"United States","geoPoint":{"lat":42.48749,"lon":-96.48642}},{"facility":"Clinical Research Associates, Inc.","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Research Across America","city":"Dallas","state":"Texas","zip":"75234","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Texas Center for Drug Development, Inc.","city":"Houston","state":"Texas","zip":"77081","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Research Across America","city":"Katy","state":"Texas","zip":"77450","country":"United States","geoPoint":{"lat":29.78579,"lon":-95.8244}},{"facility":"Advanced Clinical Research","city":"West Jordan","state":"Utah","zip":"84088","country":"United States","geoPoint":{"lat":40.60967,"lon":-111.9391}},{"facility":"Premier Clinical Research","city":"Spokane","state":"Washington","zip":"99204-4880","country":"United States","geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Dr. Calvin Powell Professional Medical Corporation","city":"Bay Roberts","state":"Newfoundland and Labrador","zip":"A0A 1G0","country":"Canada","geoPoint":{"lat":47.59989,"lon":-53.26478}},{"facility":"Canadian Center for Vaccinology - IWK Health Centre","city":"Halifax","state":"Nova Scotia","zip":"B3K 6R8","country":"Canada","geoPoint":{"lat":44.64269,"lon":-63.57688}},{"facility":"Milestone Research","city":"London","state":"Ontario","zip":"N5W 6A2","country":"Canada","geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"London Road Diagnostic Clinic and Medical Centre","city":"Sarnia","state":"Ontario","zip":"N7T 4X3","country":"Canada","geoPoint":{"lat":42.97866,"lon":-82.40407}},{"facility":"Devonshire Clinical Research Inc.","city":"Woodstock","state":"Ontario","zip":"N4S 5P5","country":"Canada","geoPoint":{"lat":43.13339,"lon":-80.7497}},{"facility":"McGill University Health Centre - Vaccine Study Centre","city":"Pierrefonds","state":"Quebec","zip":"H9H 4Y6","country":"Canada","geoPoint":{"lat":45.45989,"lon":-73.89284}},{"facility":"Centre hospitalier universitaire de Québec","city":"Québec","state":"Quebec","zip":"G1E 7G9","country":"Canada","geoPoint":{"lat":46.81228,"lon":-71.21454}},{"facility":"Pro-Recherche Inc.","city":"Saint Romuald","state":"Quebec","zip":"G6W 5M6","country":"Canada","geoPoint":{"lat":46.75818,"lon":-71.23921}},{"facility":"Clinique Medicale St-Louis Inc.","city":"Sainte-Foy, Québec","state":"Quebec","zip":"G1W 4R4","country":"Canada"},{"facility":"Aarhus Universitetshospital Skejby","city":"Aarhus N","zip":"8200","country":"Denmark","geoPoint":{"lat":56.20367,"lon":10.17317}},{"facility":"Espoo Vaccine Research Clinic","city":"Espoo","zip":"02230","country":"Finland","geoPoint":{"lat":60.2052,"lon":24.6522}},{"facility":"Helsinki South Vaccine Research Clinic","city":"Helsinki","zip":"00100","country":"Finland","geoPoint":{"lat":60.16952,"lon":24.93545}},{"facility":"Kokkola Vaccine Research Clinic","city":"Kokkola","zip":"67100","country":"Finland","geoPoint":{"lat":63.83847,"lon":23.13066}},{"facility":"Seinäjoki Vaccine Research Clinic","city":"Seinäjoki","zip":"60100","country":"Finland","geoPoint":{"lat":62.79446,"lon":22.82822}},{"facility":"NZOZ Centrum Medyczne Graniczna Sp. z o.o.","city":"Katowice","zip":"40-018","country":"Poland","geoPoint":{"lat":50.2597,"lon":19.02173}},{"facility":"Specjalistyczna Poradnia Medyczna Przyladek Zdrowia","city":"Krakow","zip":"30-438","country":"Poland","geoPoint":{"lat":50.06143,"lon":19.93658}},{"facility":"NZOZ Salmed s.c.","city":"Łęczna","zip":"21-010","country":"Poland","geoPoint":{"lat":51.30121,"lon":22.88135}},{"facility":"CAP Balenya","city":"Balenya","state":"Barcelona","zip":"08550","country":"Spain"},{"facility":"CAP Centelles","city":"Centelles","state":"Barcelona","zip":"08540","country":"Spain","geoPoint":{"lat":41.79746,"lon":2.21902}},{"facility":"Hospital Universitari de Bellvitge","city":"L'Hospitalet de Llobregat","state":"Barcelona","zip":"08907","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"CAP El Remei","city":"Vic","state":"Barcelona","zip":"08500","country":"Spain","geoPoint":{"lat":41.93012,"lon":2.25486}},{"facility":"FOM (Fundacion Oftalmologica del Mediterraneo) - FISABIO","city":"Valencia","state":"Valencia","zip":"46015","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Hospital Clinic de Barcelona","city":"Barcelona","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}}]},"referencesModule":{"references":[{"pmid":"35164991","type":"DERIVED","citation":"Beeslaar J, Mather S, Absalon J, Eiden JJ, York LJ, Crowther G, Maansson R, Maguire JD, Peyrani P, Perez JL. Safety data from the MenB-FHbp clinical development program in healthy individuals aged 10 years and older. Vaccine. 2022 Mar 15;40(12):1872-1878. doi: 10.1016/j.vaccine.2022.01.046. Epub 2022 Feb 11."},{"pmid":"32700260","type":"DERIVED","citation":"Beeslaar J, Absalon J, Anderson AS, Eiden JJ, Balmer P, Harris SL, Jones TR, O'Neill RE, Pregaldien JL, Radley D, Maansson R, Ginis J, Srivastava A, Perez JL. MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. Infect Dis Ther. 2020 Sep;9(3):641-656. doi: 10.1007/s40121-020-00319-0. Epub 2020 Jul 22."},{"pmid":"32681472","type":"DERIVED","citation":"Beeslaar J, Peyrani P, Absalon J, Maguire J, Eiden J, Balmer P, Maansson R, Perez JL. Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. Infect Dis Ther. 2020 Sep;9(3):625-639. doi: 10.1007/s40121-020-00322-5. Epub 2020 Jul 17."},{"pmid":"29236639","type":"DERIVED","citation":"Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Pregaldien JL, Ginis J, Staerke NB, Perez JL; B1971009 and B1971016 Trial Investigators. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. N Engl J Med. 2017 Dec 14;377(24):2349-2362. doi: 10.1056/NEJMoa1614474."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1971016&StudyName=A%20Trial%20to%20Assess%20the%20Safety%2C%20Tolerability%2C%20and%20Immunogenicity%20of%20Bivalent%20rLP2086%20Vaccine%20When%20Given%20to%20Healthy%20Young%20Adults%20Aged%20greater%20than%3D18%20to%20less%20than26%20Years"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 3304 participants were randomized in this study, out of which 3293 participants received vaccination.","groups":[{"id":"FG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"FG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"2471"},{"groupId":"FG001","numSubjects":"822"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1800"},{"groupId":"FG001","numSubjects":"619"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"671"},{"groupId":"FG001","numSubjects":"203"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"313"},{"groupId":"FG001","numSubjects":"92"}]},{"type":"No Longer Willing to Participate","reasons":[{"groupId":"FG000","numSubjects":"205"},{"groupId":"FG001","numSubjects":"58"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"48"},{"groupId":"FG001","numSubjects":"16"}]},{"type":"No Longer Meets Eligibility Criteria","reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Pregnancy","reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","groups":[{"id":"BG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"BG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"2471"},{"groupId":"BG001","value":"822"},{"groupId":"BG002","value":"3293"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"21.47","spread":"2.14"},{"groupId":"BG001","value":"21.52","spread":"2.20"},{"groupId":"BG002","value":"21.48","spread":"2.15"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"1452"},{"groupId":"BG001","value":"482"},{"groupId":"BG002","value":"1934"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"1019"},{"groupId":"BG001","value":"340"},{"groupId":"BG002","value":"1359"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Greater Than or Equal to(>=)4 Fold Rise in Serum Bactericidal Assay Using Human Complement(hSBA) for 4 Primary Strains and Composite Response (hSBA>=Lower Limit of Quantification for All 4 Primary Strains Combined):Group 1","description":"Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point. This outcome measure was planned to be analyzed for Group 1 only.","populationDescription":"Evaluable immunogenicity population: all eligible participants randomized, who received correct investigational product, had pre/post vaccination blood drawn at pre-specified time points, had valid and determinate assay results for proposed analysis, received no prohibited treatment or prohibited vaccines, and had no major protocol violations.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"One month after third bivalent rLP2086 vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1723"}]}],"classes":[{"title":"Composite hSBA response (N=1664)","categories":[{"measurements":[{"groupId":"OG000","value":"84.9","lowerLimit":"83.1","upperLimit":"86.6"}]}]},{"title":"PMB80 [A22] (N=1695)","categories":[{"measurements":[{"groupId":"OG000","value":"80.5","lowerLimit":"78.6","upperLimit":"82.4"}]}]},{"title":"PMB2001 [A56] (N=1642)","categories":[{"measurements":[{"groupId":"OG000","value":"90.0","lowerLimit":"88.4","upperLimit":"91.4"}]}]},{"title":"PMB2948 [B24] (N=1675)","categories":[{"measurements":[{"groupId":"OG000","value":"79.3","lowerLimit":"77.3","upperLimit":"81.2"}]}]},{"title":"PMB2707 [B44] (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"79.6","lowerLimit":"77.6","upperLimit":"81.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After First Vaccination","populationDescription":"Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after first vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2425"},{"groupId":"OG001","value":"798"}]}],"classes":[{"title":"Pain at injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"84.2","lowerLimit":"82.7","upperLimit":"85.6"},{"groupId":"OG001","value":"11.8","lowerLimit":"9.6","upperLimit":"14.2"}]}]},{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"42.3","lowerLimit":"40.3","upperLimit":"44.3"},{"groupId":"OG001","value":"10.7","lowerLimit":"8.6","upperLimit":"13.0"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"37.1","lowerLimit":"35.1","upperLimit":"39.0"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.5","upperLimit":"2.1"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"4.0","upperLimit":"5.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"12.5","upperLimit":"15.3"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.5"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"4.9","upperLimit":"6.8"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.3"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"6.1","upperLimit":"8.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.6","upperLimit":"1.4"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"15.5","lowerLimit":"14.1","upperLimit":"17.1"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.5"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.5","lowerLimit":"7.4","upperLimit":"9.7"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"5.8","upperLimit":"7.9"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Second Vaccination","populationDescription":"Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after second vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"706"}]}],"classes":[{"title":"Pain at injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"79.3","lowerLimit":"77.5","upperLimit":"81.1"},{"groupId":"OG001","value":"7.8","lowerLimit":"5.9","upperLimit":"10.0"}]}]},{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"42.2","lowerLimit":"40.1","upperLimit":"44.4"},{"groupId":"OG001","value":"6.8","lowerLimit":"5.1","upperLimit":"8.9"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"32.7","lowerLimit":"30.7","upperLimit":"34.8"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.4","upperLimit":"2.0"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"3.6","upperLimit":"5.4"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"11.8","lowerLimit":"10.4","upperLimit":"13.3"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"4.6","lowerLimit":"3.7","upperLimit":"5.6"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.3","lowerLimit":"5.3","upperLimit":"7.4"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.6","upperLimit":"1.4"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"12.6","upperLimit":"15.6"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"7.7","lowerLimit":"6.6","upperLimit":"8.9"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"6.0","lowerLimit":"5.0","upperLimit":"7.1"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.3","lowerLimit":"0.1","upperLimit":"0.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Pre-specified Local Reactions (LRs) Within 7 Days After Third Vaccination","populationDescription":"Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1823"},{"groupId":"OG001","value":"624"}]}],"classes":[{"title":"Pain at injection site: Any","categories":[{"measurements":[{"groupId":"OG000","value":"80.4","lowerLimit":"78.5","upperLimit":"82.2"},{"groupId":"OG001","value":"6.7","lowerLimit":"4.9","upperLimit":"9.0"}]}]},{"title":"Pain at injection site: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"36.1","lowerLimit":"33.9","upperLimit":"38.4"},{"groupId":"OG001","value":"6.4","lowerLimit":"4.6","upperLimit":"8.6"}]}]},{"title":"Pain at injection site: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"38.9","lowerLimit":"36.6","upperLimit":"41.2"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Pain at injection site: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"5.3","lowerLimit":"4.3","upperLimit":"6.5"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Redness: Any","categories":[{"measurements":[{"groupId":"OG000","value":"17.1","lowerLimit":"15.4","upperLimit":"18.9"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Redness: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"6.2","lowerLimit":"5.1","upperLimit":"7.4"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Redness: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"7.3","upperLimit":"9.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Redness: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"1.7","upperLimit":"3.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Swelling: Any","categories":[{"measurements":[{"groupId":"OG000","value":"16.6","lowerLimit":"14.9","upperLimit":"18.4"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Swelling: Mild","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"7.6","upperLimit":"10.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Swelling: Moderate","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"6.1","upperLimit":"8.5"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Swelling: Severe","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.2","upperLimit":"0.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination","populationDescription":"Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination. Here, 'N' signifies participants with known values reporting specific characteristic.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after first vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2425"},{"groupId":"OG001","value":"798"}]}],"classes":[{"title":"Fever >=38 degrees C(N=2415, 796)","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"1.8","upperLimit":"3.0"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.5"}]}]},{"title":"Fever 38 to <38.5 degreesC(N=2415, 796)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.1","upperLimit":"2.2"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.1"}]}]},{"title":"Fever 38.5 to<39 degrees C(N=2415, 796)","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.4","upperLimit":"1.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Fever 39 to 40 degrees C (N=2415, 796)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Fever >40 degrees C(N=2415, 796)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting:Any(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"2.6","lowerLimit":"2.0","upperLimit":"3.3"},{"groupId":"OG001","value":"2.1","lowerLimit":"1.2","upperLimit":"3.4"}]}]},{"title":"Vomiting:Mild(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.6","upperLimit":"2.8"},{"groupId":"OG001","value":"2.1","lowerLimit":"1.2","upperLimit":"3.4"}]}]},{"title":"Vomiting:Moderate(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting:Severe(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Diarrhea:Any(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"11.4","upperLimit":"14.1"},{"groupId":"OG001","value":"11.8","lowerLimit":"9.6","upperLimit":"14.2"}]}]},{"title":"Diarrhea:Mild(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"9.0","upperLimit":"11.5"},{"groupId":"OG001","value":"9.8","lowerLimit":"7.8","upperLimit":"12.0"}]}]},{"title":"Diarrhea:Moderate(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"1.8","upperLimit":"3.0"},{"groupId":"OG001","value":"1.9","lowerLimit":"1.1","upperLimit":"3.1"}]}]},{"title":"Diarrhea:Severe(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.7"}]}]},{"title":"Headache:Any(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"43.9","lowerLimit":"41.9","upperLimit":"45.9"},{"groupId":"OG001","value":"36.2","lowerLimit":"32.9","upperLimit":"39.7"}]}]},{"title":"Headache:Mild(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"24.3","lowerLimit":"22.6","upperLimit":"26.1"},{"groupId":"OG001","value":"22.1","lowerLimit":"19.2","upperLimit":"25.1"}]}]},{"title":"Headache:Moderate(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"17.9","lowerLimit":"16.4","upperLimit":"19.5"},{"groupId":"OG001","value":"13.5","lowerLimit":"11.2","upperLimit":"16.1"}]}]},{"title":"Headache:Severe(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.2","upperLimit":"2.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.5"}]}]},{"title":"Fatigue:Any(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"50.9","lowerLimit":"48.9","upperLimit":"52.9"},{"groupId":"OG001","value":"39.8","lowerLimit":"36.4","upperLimit":"43.3"}]}]},{"title":"Fatigue:Mild(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"25.4","lowerLimit":"23.7","upperLimit":"27.2"},{"groupId":"OG001","value":"23.2","lowerLimit":"20.3","upperLimit":"26.3"}]}]},{"title":"Fatigue:Moderate(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"22.1","lowerLimit":"20.5","upperLimit":"23.8"},{"groupId":"OG001","value":"15.8","lowerLimit":"13.3","upperLimit":"18.5"}]}]},{"title":"Fatigue:Severe(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.7","upperLimit":"4.2"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.4","upperLimit":"1.8"}]}]},{"title":"Chills:Any(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"18.1","lowerLimit":"16.5","upperLimit":"19.7"},{"groupId":"OG001","value":"9.8","lowerLimit":"7.8","upperLimit":"12.0"}]}]},{"title":"Chills:Mild(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"12.0","lowerLimit":"10.8","upperLimit":"13.4"},{"groupId":"OG001","value":"8.1","lowerLimit":"6.3","upperLimit":"10.3"}]}]},{"title":"Chills:Moderate(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"4.1","upperLimit":"5.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.9","upperLimit":"2.8"}]}]},{"title":"Chills: Severe(N=2425, 798)","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.7","upperLimit":"1.6"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Muscle pain:Any(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"25.9","lowerLimit":"24.1","upperLimit":"27.6"},{"groupId":"OG001","value":"14.5","lowerLimit":"12.2","upperLimit":"17.2"}]}]},{"title":"Muscle pain:Mild(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"13.0","lowerLimit":"11.7","upperLimit":"14.4"},{"groupId":"OG001","value":"9.6","lowerLimit":"7.7","upperLimit":"11.9"}]}]},{"title":"Muscle pain:Moderate(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"11.3","lowerLimit":"10.0","upperLimit":"12.6"},{"groupId":"OG001","value":"4.4","lowerLimit":"3.1","upperLimit":"6.0"}]}]},{"title":"Muscle pain:Severe(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.1","upperLimit":"2.2"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.3"}]}]},{"title":"Joint pain:Any(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"19.6","lowerLimit":"18.1","upperLimit":"21.3"},{"groupId":"OG001","value":"10.9","lowerLimit":"8.8","upperLimit":"13.3"}]}]},{"title":"Joint pain:Mild(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"9.1","upperLimit":"11.6"},{"groupId":"OG001","value":"6.9","lowerLimit":"5.2","upperLimit":"8.9"}]}]},{"title":"Joint pain:Moderate(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"7.9","lowerLimit":"6.8","upperLimit":"9.0"},{"groupId":"OG001","value":"3.5","lowerLimit":"2.3","upperLimit":"5.0"}]}]},{"title":"Joint pain: Severe(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.0","upperLimit":"2.0"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.3"}]}]},{"title":"Antipyretic medication(N=2425,798)","categories":[{"measurements":[{"groupId":"OG000","value":"13.4","lowerLimit":"12.1","upperLimit":"14.8"},{"groupId":"OG001","value":"8.9","lowerLimit":"7.0","upperLimit":"11.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination","populationDescription":"Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination. Here, 'N' signifies participants with known values reporting specific characteristic.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after second vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2076"},{"groupId":"OG001","value":"706"}]}],"classes":[{"title":"Fever >=38 degrees C(N=2067, 705)","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.7","upperLimit":"1.7"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.4","upperLimit":"2.0"}]}]},{"title":"Fever 38 to <38.5 degreesC(N=2067, 705)","categories":[{"measurements":[{"groupId":"OG000","value":"0.7","lowerLimit":"0.4","upperLimit":"1.1"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.4"}]}]},{"title":"Fever 38.5 to<39 degrees C(N=2067, 705)","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.8"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Fever 39 to 40 degrees C (N=2067, 705)","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.1","lowerLimit":"0.0","upperLimit":"0.8"}]}]},{"title":"Fever >40 degrees C(N=2067, 705)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Vomiting:Any(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.5","upperLimit":"2.8"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.8","upperLimit":"2.8"}]}]},{"title":"Vomiting:Mild(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.1","upperLimit":"2.3"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.6","upperLimit":"2.4"}]}]},{"title":"Vomiting:Moderate(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.2","upperLimit":"0.9"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Vomiting:Severe(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Diarrhea:Any(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"7.4","upperLimit":"9.9"},{"groupId":"OG001","value":"8.1","lowerLimit":"6.2","upperLimit":"10.3"}]}]},{"title":"Diarrhea:Mild(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"6.4","lowerLimit":"5.3","upperLimit":"7.5"},{"groupId":"OG001","value":"4.7","lowerLimit":"3.2","upperLimit":"6.5"}]}]},{"title":"Diarrhea:Moderate(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"1.7","lowerLimit":"1.2","upperLimit":"2.4"},{"groupId":"OG001","value":"2.8","lowerLimit":"1.7","upperLimit":"4.3"}]}]},{"title":"Diarrhea:Severe(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"0.5","lowerLimit":"0.3","upperLimit":"0.9"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.4"}]}]},{"title":"Headache:Any(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"33.1","lowerLimit":"31.1","upperLimit":"35.2"},{"groupId":"OG001","value":"24.9","lowerLimit":"21.8","upperLimit":"28.3"}]}]},{"title":"Headache:Mild(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"18.4","lowerLimit":"16.8","upperLimit":"20.1"},{"groupId":"OG001","value":"13.6","lowerLimit":"11.2","upperLimit":"16.3"}]}]},{"title":"Headache:Moderate(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"11.9","upperLimit":"14.8"},{"groupId":"OG001","value":"10.1","lowerLimit":"7.9","upperLimit":"12.5"}]}]},{"title":"Headache:Severe(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"1.0","upperLimit":"2.1"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.6","upperLimit":"2.4"}]}]},{"title":"Fatigue:Any(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"39.2","lowerLimit":"37.1","upperLimit":"41.3"},{"groupId":"OG001","value":"27.3","lowerLimit":"24.1","upperLimit":"30.8"}]}]},{"title":"Fatigue:Mild(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"20.6","lowerLimit":"18.8","upperLimit":"22.4"},{"groupId":"OG001","value":"13.9","lowerLimit":"11.4","upperLimit":"16.7"}]}]},{"title":"Fatigue:Moderate(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"16.4","lowerLimit":"14.8","upperLimit":"18.0"},{"groupId":"OG001","value":"11.5","lowerLimit":"9.2","upperLimit":"14.1"}]}]},{"title":"Fatigue:Severe(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"1.6","upperLimit":"2.9"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.1","upperLimit":"3.3"}]}]},{"title":"Chills:Any(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"12.4","lowerLimit":"11.0","upperLimit":"13.9"},{"groupId":"OG001","value":"8.5","lowerLimit":"6.5","upperLimit":"10.8"}]}]},{"title":"Chills:Mild(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"7.0","upperLimit":"9.4"},{"groupId":"OG001","value":"6.9","lowerLimit":"5.2","upperLimit":"9.1"}]}]},{"title":"Chills:Moderate(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"3.5","lowerLimit":"2.8","upperLimit":"4.4"},{"groupId":"OG001","value":"1.6","lowerLimit":"0.8","upperLimit":"2.8"}]}]},{"title":"Chills: Severe(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.4","upperLimit":"1.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.5"}]}]},{"title":"Muscle pain:Any(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"15.6","lowerLimit":"14.0","upperLimit":"17.2"},{"groupId":"OG001","value":"8.5","lowerLimit":"6.5","upperLimit":"10.8"}]}]},{"title":"Muscle pain:Mild(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"6.5","upperLimit":"8.8"},{"groupId":"OG001","value":"5.8","lowerLimit":"4.2","upperLimit":"7.8"}]}]},{"title":"Muscle pain:Moderate(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"6.1","upperLimit":"8.3"},{"groupId":"OG001","value":"2.3","lowerLimit":"1.3","upperLimit":"3.7"}]}]},{"title":"Muscle pain:Severe(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.5","upperLimit":"1.3"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"}]}]},{"title":"Joint pain:Any(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"15.1","lowerLimit":"13.6","upperLimit":"16.7"},{"groupId":"OG001","value":"6.5","lowerLimit":"4.8","upperLimit":"8.6"}]}]},{"title":"Joint pain:Mild(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"8.1","lowerLimit":"7.0","upperLimit":"9.3"},{"groupId":"OG001","value":"3.7","lowerLimit":"2.4","upperLimit":"5.3"}]}]},{"title":"Joint pain:Moderate(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"6.2","lowerLimit":"5.2","upperLimit":"7.3"},{"groupId":"OG001","value":"2.5","lowerLimit":"1.5","upperLimit":"4.0"}]}]},{"title":"Joint pain: Severe(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.5","upperLimit":"1.4"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.0"}]}]},{"title":"Antipyretic medication(N=2076, 706)","categories":[{"measurements":[{"groupId":"OG000","value":"12.3","lowerLimit":"10.9","upperLimit":"13.8"},{"groupId":"OG001","value":"7.6","lowerLimit":"5.8","upperLimit":"9.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination","populationDescription":"Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw. Here, 'N' signifies participants with known values reporting specific characteristic.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 7 days after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1823"},{"groupId":"OG001","value":"624"}]}],"classes":[{"title":"Fever >=38 degrees C(N=1814, 621)","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.4","upperLimit":"2.7"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.6"}]}]},{"title":"Fever 38 to <38.5 degreesC(N=1814, 621)","categories":[{"measurements":[{"groupId":"OG000","value":"1.4","lowerLimit":"0.9","upperLimit":"2.0"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.1","upperLimit":"1.4"}]}]},{"title":"Fever 38.5 to<39 degrees C(N=1814, 621)","categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.9"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Fever 39 to 40 degrees C (N=1814, 621)","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Fever >40 degrees C(N=1814, 621)","categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Vomiting:Any(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"2.0","lowerLimit":"1.4","upperLimit":"2.7"},{"groupId":"OG001","value":"1.4","lowerLimit":"0.7","upperLimit":"2.7"}]}]},{"title":"Vomiting:Mild(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.2","upperLimit":"2.5"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.5","upperLimit":"2.3"}]}]},{"title":"Vomiting:Moderate(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.1","upperLimit":"0.6"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Vomiting:Severe(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Diarrhea:Any(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"7.5","lowerLimit":"6.3","upperLimit":"8.8"},{"groupId":"OG001","value":"6.9","lowerLimit":"5.0","upperLimit":"9.2"}]}]},{"title":"Diarrhea:Mild(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"5.0","upperLimit":"7.3"},{"groupId":"OG001","value":"5.3","lowerLimit":"3.7","upperLimit":"7.3"}]}]},{"title":"Diarrhea:Moderate(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.8","upperLimit":"1.8"},{"groupId":"OG001","value":"1.3","lowerLimit":"0.6","upperLimit":"2.5"}]}]},{"title":"Diarrhea:Severe(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"0.2","lowerLimit":"0.0","upperLimit":"0.5"},{"groupId":"OG001","value":"0.3","lowerLimit":"0.0","upperLimit":"1.2"}]}]},{"title":"Headache:Any(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"32.5","lowerLimit":"30.4","upperLimit":"34.7"},{"groupId":"OG001","value":"21.6","lowerLimit":"18.5","upperLimit":"25.1"}]}]},{"title":"Headache:Mild(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"17.6","lowerLimit":"15.9","upperLimit":"19.4"},{"groupId":"OG001","value":"12.5","lowerLimit":"10.0","upperLimit":"15.4"}]}]},{"title":"Headache:Moderate(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"13.3","lowerLimit":"11.8","upperLimit":"15.0"},{"groupId":"OG001","value":"8.3","lowerLimit":"6.3","upperLimit":"10.8"}]}]},{"title":"Headache:Severe(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.1","upperLimit":"2.3"},{"groupId":"OG001","value":"0.8","lowerLimit":"0.3","upperLimit":"1.9"}]}]},{"title":"Fatigue:Any(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"39.3","lowerLimit":"37.1","upperLimit":"41.6"},{"groupId":"OG001","value":"24.5","lowerLimit":"21.2","upperLimit":"28.1"}]}]},{"title":"Fatigue:Mild(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"18.9","lowerLimit":"17.2","upperLimit":"20.8"},{"groupId":"OG001","value":"13.1","lowerLimit":"10.6","upperLimit":"16.0"}]}]},{"title":"Fatigue:Moderate(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"17.0","upperLimit":"20.6"},{"groupId":"OG001","value":"9.6","lowerLimit":"7.4","upperLimit":"12.2"}]}]},{"title":"Fatigue:Severe(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.1","upperLimit":"2.3"},{"groupId":"OG001","value":"1.8","lowerLimit":"0.9","upperLimit":"3.1"}]}]},{"title":"Chills:Any(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"12.6","lowerLimit":"11.1","upperLimit":"14.2"},{"groupId":"OG001","value":"6.4","lowerLimit":"4.6","upperLimit":"8.6"}]}]},{"title":"Chills:Mild(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"7.7","lowerLimit":"6.5","upperLimit":"9.0"},{"groupId":"OG001","value":"4.3","lowerLimit":"2.9","upperLimit":"6.2"}]}]},{"title":"Chills:Moderate(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"4.2","lowerLimit":"3.3","upperLimit":"5.2"},{"groupId":"OG001","value":"2.1","lowerLimit":"1.1","upperLimit":"3.5"}]}]},{"title":"Chills: Severe(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.4","upperLimit":"1.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Muscle pain:Any(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"16.9","lowerLimit":"15.2","upperLimit":"18.7"},{"groupId":"OG001","value":"7.5","lowerLimit":"5.6","upperLimit":"9.9"}]}]},{"title":"Muscle pain:Mild(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"8.9","lowerLimit":"7.7","upperLimit":"10.3"},{"groupId":"OG001","value":"4.5","lowerLimit":"3.0","upperLimit":"6.4"}]}]},{"title":"Muscle pain:Moderate(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"6.8","lowerLimit":"5.7","upperLimit":"8.1"},{"groupId":"OG001","value":"2.9","lowerLimit":"1.7","upperLimit":"4.5"}]}]},{"title":"Muscle pain:Severe(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"1.2","lowerLimit":"0.7","upperLimit":"1.8"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.0","upperLimit":"0.9"}]}]},{"title":"Joint pain:Any(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"12.6","lowerLimit":"11.1","upperLimit":"14.2"},{"groupId":"OG001","value":"5.3","lowerLimit":"3.7","upperLimit":"7.3"}]}]},{"title":"Joint pain:Mild(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"6.6","lowerLimit":"5.5","upperLimit":"7.9"},{"groupId":"OG001","value":"2.9","lowerLimit":"1.7","upperLimit":"4.5"}]}]},{"title":"Joint pain:Moderate(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"5.4","lowerLimit":"4.4","upperLimit":"6.5"},{"groupId":"OG001","value":"2.4","lowerLimit":"1.4","upperLimit":"3.9"}]}]},{"title":"Joint pain: Severe(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"0.6","lowerLimit":"0.3","upperLimit":"1.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]},{"title":"Antipyretic medication(N=1823, 624)","categories":[{"measurements":[{"groupId":"OG000","value":"12.8","lowerLimit":"11.3","upperLimit":"14.5"},{"groupId":"OG001","value":"6.6","lowerLimit":"4.8","upperLimit":"8.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After First Vaccination","populationDescription":"Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after first vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.62","lowerLimit":"7.5","upperLimit":"9.8"},{"groupId":"OG001","value":"7.30","lowerLimit":"5.6","upperLimit":"9.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination","populationDescription":"Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after second vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"733"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.10","lowerLimit":"8.9","upperLimit":"11.4"},{"groupId":"OG001","value":"10.10","lowerLimit":"8.0","upperLimit":"12.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination","populationDescription":"Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1889"},{"groupId":"OG001","value":"649"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.26","lowerLimit":"8.0","upperLimit":"10.7"},{"groupId":"OG001","value":"7.24","lowerLimit":"5.4","upperLimit":"9.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Any Vaccination","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after any vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.17","lowerLimit":"19.6","upperLimit":"22.8"},{"groupId":"OG001","value":"18.86","lowerLimit":"16.2","upperLimit":"21.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Adverse Event (AE) During the Vaccination Phase","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first vaccination up to 1 month after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.20","lowerLimit":"29.4","upperLimit":"33.1"},{"groupId":"OG001","value":"31.14","lowerLimit":"28.0","upperLimit":"34.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination","populationDescription":"Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after first vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.12","lowerLimit":"0.0","upperLimit":"0.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination","populationDescription":"Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after second vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"733"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.00","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination","populationDescription":"Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1889"},{"groupId":"OG001","value":"649"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","lowerLimit":"0.0","upperLimit":"0.4"},{"groupId":"OG001","value":"0.15","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after any vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.53","lowerLimit":"0.3","upperLimit":"0.9"},{"groupId":"OG001","value":"0.24","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-up Phase","populationDescription":"Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post-vaccination 3 blood draw to 6 months after last study vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From 1 month after third vaccination up to 6 months after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2067"},{"groupId":"OG001","value":"704"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","lowerLimit":"0.3","upperLimit":"1.1"},{"groupId":"OG001","value":"0.71","lowerLimit":"0.2","upperLimit":"1.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first vaccination up to 1 month after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","lowerLimit":"0.5","upperLimit":"1.3"},{"groupId":"OG001","value":"0.73","lowerLimit":"0.3","upperLimit":"1.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first vaccination up to 6 month after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.34","lowerLimit":"0.9","upperLimit":"1.9"},{"groupId":"OG001","value":"1.34","lowerLimit":"0.7","upperLimit":"2.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination","populationDescription":"Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after first vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.89","lowerLimit":"3.2","upperLimit":"4.7"},{"groupId":"OG001","value":"3.77","lowerLimit":"2.6","upperLimit":"5.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination","populationDescription":"Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after second vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"733"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.66","lowerLimit":"3.8","upperLimit":"5.6"},{"groupId":"OG001","value":"4.91","lowerLimit":"3.5","upperLimit":"6.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination","populationDescription":"Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until until post third-vaccination blood draw.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1889"},{"groupId":"OG001","value":"649"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.03","lowerLimit":"4.1","upperLimit":"6.1"},{"groupId":"OG001","value":"3.85","lowerLimit":"2.5","upperLimit":"5.6"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after any vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.93","lowerLimit":"9.7","upperLimit":"12.2"},{"groupId":"OG001","value":"10.22","lowerLimit":"8.2","upperLimit":"12.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first vaccination up to 1 month after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.22","lowerLimit":"17.7","upperLimit":"20.8"},{"groupId":"OG001","value":"17.76","lowerLimit":"15.2","upperLimit":"20.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase","populationDescription":"Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post-vaccination 3 blood draw to 6 months after last study vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From 1 month after third vaccination up to 6 months after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2067"},{"groupId":"OG001","value":"704"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.97","lowerLimit":"5.9","upperLimit":"8.2"},{"groupId":"OG001","value":"6.68","lowerLimit":"4.9","upperLimit":"8.8"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting at Least 1 Medically Attended Adverse Event Throughout the Study Period","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first vaccination up to 6 month after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.89","lowerLimit":"20.3","upperLimit":"23.6"},{"groupId":"OG001","value":"21.17","lowerLimit":"18.4","upperLimit":"24.1"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination","populationDescription":"Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after first vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"0.0","upperLimit":"0.1"},{"groupId":"OG001","value":"0.00","lowerLimit":"0.0","upperLimit":"0.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination","populationDescription":"Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after second vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"733"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.00","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination","populationDescription":"Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1889"},{"groupId":"OG001","value":"649"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"0.0","upperLimit":"0.2"},{"groupId":"OG001","value":"0.15","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 days after any vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","lowerLimit":"0.1","upperLimit":"0.5"},{"groupId":"OG001","value":"0.12","lowerLimit":"0.0","upperLimit":"0.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first vaccination up to 1 month after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","lowerLimit":"0.1","upperLimit":"0.6"},{"groupId":"OG001","value":"0.24","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase","populationDescription":"Safety population: all participants who had at least 1 dose of investigational product (rLP2086 or saline) for whom safety information was available from after post third-vaccination blood draw to 6 months after last study vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From 1 month after third vaccination up to 6 months after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2067"},{"groupId":"OG001","value":"704"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.00","lowerLimit":"0.0","upperLimit":"0.5"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first vaccination up to 6 month after the third vaccination the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","lowerLimit":"0.2","upperLimit":"0.7"},{"groupId":"OG001","value":"0.24","lowerLimit":"0.0","upperLimit":"0.9"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After First Vaccination","populationDescription":"Safety population for first vaccination included all participants who received the first dose of investigational product (rLP2086 or saline) and for whom safety information was available from first vaccination until prior to second vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 minutes after first vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2471"},{"groupId":"OG001","value":"822"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","lowerLimit":"0.2","upperLimit":"0.7"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.2","upperLimit":"1.4"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Second Vaccination","populationDescription":"Safety population for second vaccination included all participants who received the second dose of investigational product (rLP2086 or saline) and for whom safety information was available from second vaccination until prior to third vaccination.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 minutes after second vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"2169"},{"groupId":"OG001","value":"733"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.1","upperLimit":"1.2"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Reporting at Least 1 Immediate Adverse Event (AE) After Third Vaccination","populationDescription":"Safety population for third vaccination included all participants who received the third dose of investigational product (rLP2086 or saline) and for whom safety information was available from third vaccination until post third-vaccination blood draw.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Within 30 minutes after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1889"},{"groupId":"OG001","value":"649"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","lowerLimit":"0.0","upperLimit":"0.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"0.6"}]}]}]},{"type":"PRIMARY","title":"Number of Days Participants Missed School or Work Due to AE During the Vaccination Phase","populationDescription":"Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or saline) and had safety data available. Here, number of participants analyzed signifies subjects that were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Days","timeFrame":"From the first vaccination up to 1 month after the third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."},{"id":"OG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"63"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"10.75"},{"groupId":"OG001","value":"5.6","spread":"13.26"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Titers >= Lower Limit of Quantification for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Before first vaccination, 1 month after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"}]}],"classes":[{"title":"PMB3175[A29]:Before Vaccination 1 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"31.1","lowerLimit":"25.7","upperLimit":"36.9"}]}]},{"title":"PMB3175[A29]:1 Month after Vaccination 3 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"99.3","lowerLimit":"97.5","upperLimit":"99.9"}]}]},{"title":"PMB3010[A06]:Before Vaccination 1 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"11.9","upperLimit":"20.9"}]}]},{"title":"PMB3010[A06]:1 Month after Vaccination 3 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"92.0","lowerLimit":"88.1","upperLimit":"94.9"}]}]},{"title":"PMB3040[A07]:Before Vaccination 1 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"55.8","lowerLimit":"49.7","upperLimit":"61.8"}]}]},{"title":"PMB3040[A07]:1 Month after Vaccination 3 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"95.7","lowerLimit":"92.6","upperLimit":"97.7"}]}]},{"title":"PMB824[A12]: Before Vaccination 1 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"2.8","upperLimit":"8.3"}]}]},{"title":"PMB824[A12]:1 Month after Vaccination 3 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"71.3","lowerLimit":"65.5","upperLimit":"76.5"}]}]},{"title":"PMB1672[A15]:Before Vaccination 1 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"37.3","lowerLimit":"31.6","upperLimit":"43.2"}]}]},{"title":"PMB1672[A15]:1 Month after Vaccination 3 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"91.8","lowerLimit":"87.9","upperLimit":"94.7"}]}]},{"title":"PMB1989[A19]:Before Vaccination 1 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"28.8","lowerLimit":"23.5","upperLimit":"34.5"}]}]},{"title":"PMB1989[A19]:1 Month after Vaccination 3 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"95.8","lowerLimit":"92.7","upperLimit":"97.8"}]}]},{"title":"PMB1256[B03]:Before Vaccination 1 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"7.7","upperLimit":"15.5"}]}]},{"title":"PMB1256[B03]:1 Month after Vaccination 3 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"86.4","lowerLimit":"81.8","upperLimit":"90.3"}]}]},{"title":"PMB866[B09]:Before Vaccination 1 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"23.5","lowerLimit":"18.6","upperLimit":"28.9"}]}]},{"title":"PMB866[B09]:1 Month after Vaccination 3 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"77.0","lowerLimit":"71.6","upperLimit":"81.9"}]}]},{"title":"PMB431[B15]:Before Vaccination 1 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"43.8","lowerLimit":"37.8","upperLimit":"49.9"}]}]},{"title":"PMB431[B15]:1 Month after Vaccination 3 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"96.7","lowerLimit":"93.9","upperLimit":"98.5"}]}]},{"title":"PMB648[B16]:Before Vaccination 1 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"21.9","lowerLimit":"17.1","upperLimit":"27.3"}]}]},{"title":"PMB648[B16]:1 Month after Vaccination 3 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"78.0","lowerLimit":"72.6","upperLimit":"82.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, >=1:128 for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Before first vaccination, 1 month after third vaccination (Vac)","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"}]}],"classes":[{"title":"Before Vaccination 1: PMB3175[A29] 1:4 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"32.9","lowerLimit":"27.4","upperLimit":"38.7"}]}]},{"title":"1 month after Vac 3: PMB3175[A29] 1:4 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"99.3","lowerLimit":"97.5","upperLimit":"99.9"}]}]},{"title":"Before Vaccination 1: PMB3175[A29] 1:8 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"31.1","lowerLimit":"25.7","upperLimit":"36.9"}]}]},{"title":"1 month after Vac 3: PMB3175[A29] 1:8 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"99.3","lowerLimit":"97.5","upperLimit":"99.9"}]}]},{"title":"Before Vaccination 1: PMB3175[A29] 1:16 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"27.9","lowerLimit":"22.7","upperLimit":"33.5"}]}]},{"title":"1 month after Vac 3: PMB3175[A29] 1:16 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"98.9","lowerLimit":"96.9","upperLimit":"99.8"}]}]},{"title":"Before Vaccination 1: PMB3175[A29] 1:32 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"16.1","lowerLimit":"12.0","upperLimit":"20.9"}]}]},{"title":"1 month after Vac 3: PMB3175[A29] 1:32 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"96.8","lowerLimit":"94.0","upperLimit":"98.5"}]}]},{"title":"Before Vaccination 1: PMB3175[A29] 1:64 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"3.3","upperLimit":"9.1"}]}]},{"title":"1 month after Vac 3: PMB3175[A29] 1:64 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"80.9","lowerLimit":"75.8","upperLimit":"85.3"}]}]},{"title":"Before Vaccination 1: PMB3175[A29] 1:128 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"0.8","upperLimit":"4.6"}]}]},{"title":"1 month after Vac 3: PMB3175[A29] 1:128 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"53.0","lowerLimit":"47.0","upperLimit":"58.9"}]}]},{"title":"Before Vaccination 1: PMB3010[A06] 1:4 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"18.9","lowerLimit":"14.5","upperLimit":"24.0"}]}]},{"title":"1 month after Vac 3: PMB3010[A06] 1:4 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"92.4","lowerLimit":"88.6","upperLimit":"95.2"}]}]},{"title":"Before Vaccination 1: PMB3010[A06] 1:8 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"17.5","lowerLimit":"13.2","upperLimit":"22.5"}]}]},{"title":"1 month after Vac 3: PMB3010[A06] 1:8 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"92.4","lowerLimit":"88.6","upperLimit":"95.2"}]}]},{"title":"Before Vaccination 1: PMB3010[A06] 1:16 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"11.9","upperLimit":"20.9"}]}]},{"title":"1 month after Vac 3: PMB3010[A06] 1:16 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"92.0","lowerLimit":"88.1","upperLimit":"94.9"}]}]},{"title":"Before Vaccination 1: PMB3010[A06] 1:32 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"10.5","lowerLimit":"7.2","upperLimit":"14.8"}]}]},{"title":"1 month after Vac 3: PMB3010 [A06] 1:32 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"86.2","lowerLimit":"81.5","upperLimit":"90.0"}]}]},{"title":"Before Vaccination 1: PMB3010[A06] 1:64 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"3.9","upperLimit":"10.1"}]}]},{"title":"1 month after Vac 3: PMB3010[A06] 1:64 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"70.5","lowerLimit":"64.8","upperLimit":"75.9"}]}]},{"title":"Before Vaccination 1: PMB3010[A06] 1:128 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"2.5","lowerLimit":"1.0","upperLimit":"5.2"}]}]},{"title":"1 month after Vac 3: PMB3010[A06] 1:128 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"41.8","lowerLimit":"35.9","upperLimit":"47.9"}]}]},{"title":"Before Vaccination 1: PMB3040[A07] 1:4 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"55.8","lowerLimit":"49.7","upperLimit":"61.8"}]}]},{"title":"1 month after Vac 3: PMB3040[A07] 1:4 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"95.7","lowerLimit":"92.6","upperLimit":"97.7"}]}]},{"title":"Before Vaccination 1: PMB3040[A07] 1:8 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"55.8","lowerLimit":"49.7","upperLimit":"61.8"}]}]},{"title":"1 month after Vac 3: PMB3040[A07] 1:8 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"95.7","lowerLimit":"92.6","upperLimit":"97.7"}]}]},{"title":"Before Vaccination 1: PMB3040[A07] 1:16 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"55.5","lowerLimit":"49.4","upperLimit":"61.5"}]}]},{"title":"1 month after Vac 3: PMB3040[A07] 1:16 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"95.7","lowerLimit":"92.6","upperLimit":"97.7"}]}]},{"title":"Before Vaccination 1: PMB3040[A07] 1:32 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"42.7","lowerLimit":"36.8","upperLimit":"48.8"}]}]},{"title":"1 month after Vac 3: PMB3040[A07] 1:32 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"92.4","lowerLimit":"88.6","upperLimit":"95.2"}]}]},{"title":"Before Vaccination 1: PMB3040[A07] 1:64 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"21.2","lowerLimit":"16.5","upperLimit":"26.5"}]}]},{"title":"1 month after Vac 3: PMB3040[A07] 1:64 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"72.9","lowerLimit":"67.3","upperLimit":"78.1"}]}]},{"title":"Before Vaccination 1: PMB3040[A07] 1:128 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"4.0","lowerLimit":"2.0","upperLimit":"7.1"}]}]},{"title":"1 month after Vac 3: PMB3040[A07] 1:128 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"29.2","lowerLimit":"24.0","upperLimit":"35.0"}]}]},{"title":"Before Vaccination 1: PMB824[A12] 1:4 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"7.1","upperLimit":"14.6"}]}]},{"title":"1 month after Vac 3: PMB824[A12] 1:4 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"73.8","lowerLimit":"68.2","upperLimit":"78.9"}]}]},{"title":"Before Vaccination 1: PMB824[A12] 1:8 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"8.3","lowerLimit":"5.3","upperLimit":"12.2"}]}]},{"title":"1 month after Vac 3: PMB824[A12] 1:8 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"73.5","lowerLimit":"67.8","upperLimit":"78.6"}]}]},{"title":"Before Vaccination 1: PMB824[A12] 1:16 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"2.8","upperLimit":"8.3"}]}]},{"title":"1 month after Vac 3: PMB824[A12] 1:16 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"71.3","lowerLimit":"65.5","upperLimit":"76.5"}]}]},{"title":"Before Vaccination 1: PMB824[A12] 1:32 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"2.2","lowerLimit":"0.8","upperLimit":"4.6"}]}]},{"title":"1 month after Vac 3: PMB824[A12] 1:32 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"46.5","lowerLimit":"40.5","upperLimit":"52.6"}]}]},{"title":"Before Vaccination 1: PMB824[A12] 1:64 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"1.3"}]}]},{"title":"1 month after Vac 3: PMB824[A12] 1:64 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"15.6","lowerLimit":"11.6","upperLimit":"20.5"}]}]},{"title":"Before Vaccination 1: PMB824[A12] 1:128 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"1.3"}]}]},{"title":"1 month after Vac 3: PMB824[A12] 1:128 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"1.5","upperLimit":"6.1"}]}]},{"title":"Before Vaccination 1: PMB1672[A15] 1:4 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"39.4","lowerLimit":"33.7","upperLimit":"45.4"}]}]},{"title":"1 month after Vac 3: PMB1672[A15] 1:4 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"91.8","lowerLimit":"87.9","upperLimit":"94.7"}]}]},{"title":"Before Vaccination 1: PMB1672[A15] 1:8 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"37.3","lowerLimit":"31.6","upperLimit":"43.2"}]}]},{"title":"1 month after Vac 3: PMB1672[A15] 1:8 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"91.8","lowerLimit":"87.9","upperLimit":"94.7"}]}]},{"title":"Before Vaccination 1: PMB1672[A15] 1:16 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","lowerLimit":"27.8","upperLimit":"39.2"}]}]},{"title":"1 month after Vac 3: PMB1672[A15] 1:16 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"91.4","lowerLimit":"87.5","upperLimit":"94.4"}]}]},{"title":"Before Vaccination 1: PMB1672[A15] 1:32 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"20.4","lowerLimit":"15.9","upperLimit":"25.6"}]}]},{"title":"1 month after Vac 3: PMB1672[A15] 1:32 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"82.4","lowerLimit":"77.5","upperLimit":"86.7"}]}]},{"title":"Before Vaccination 1: PMB1672[A15] 1:64 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","lowerLimit":"4.4","upperLimit":"10.9"}]}]},{"title":"1 month after Vac 3: PMB1672[A15] 1:64 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"54.5","lowerLimit":"48.4","upperLimit":"60.4"}]}]},{"title":"Before Vaccination 1: PMB1672[A15] 1:128 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"0.6","upperLimit":"4.1"}]}]},{"title":"1 month after Vac 3: PMB1672[A15] 1:128 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"19.0","lowerLimit":"14.6","upperLimit":"24.1"}]}]},{"title":"Before Vaccination 1: PMB1989[A19] 1:4 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"39.2","lowerLimit":"33.4","upperLimit":"45.2"}]}]},{"title":"1 month after Vac 3: PMB1989[A19] 1:4 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"96.1","lowerLimit":"93.2","upperLimit":"98.1"}]}]},{"title":"Before Vaccination 1: PMB1989[A19] 1:8 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"37.1","lowerLimit":"31.4","upperLimit":"43.0"}]}]},{"title":"1 month after Vac 3: PMB1989[A19] 1:8 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"96.1","lowerLimit":"93.2","upperLimit":"98.1"}]}]},{"title":"Before Vaccination 1: PMB1989[A19] 1:16 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"28.8","lowerLimit":"23.5","upperLimit":"34.5"}]}]},{"title":"1 month after Vac 3: PMB1989[A19] 1:16 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"95.8","lowerLimit":"92.7","upperLimit":"97.8"}]}]},{"title":"Before Vaccination 1: PMB1989[A19] 1:32 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"18.3","lowerLimit":"14.0","upperLimit":"23.4"}]}]},{"title":"1 month after Vac 3: PMB1989[A19] 1:32 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"92.3","lowerLimit":"88.5","upperLimit":"95.1"}]}]},{"title":"Before Vaccination 1: PMB1989[A19] 1:64 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"5.9","upperLimit":"13.0"}]}]},{"title":"1 month after Vac 3: PMB1989[A19] 1:64 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"77.5","lowerLimit":"72.2","upperLimit":"82.2"}]}]},{"title":"Before Vaccination 1: PMB1989[A19] 1:128 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"9.0","lowerLimit":"5.9","upperLimit":"13.0"}]}]},{"title":"1 month after Vac 3: PMB1989[A19] 1:128 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"49.6","lowerLimit":"43.7","upperLimit":"55.6"}]}]},{"title":"Before Vaccination 1: PMB1256[B03] 1:4 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"13.0","lowerLimit":"9.3","upperLimit":"17.5"}]}]},{"title":"1 month after Vac 3: PMB1256[B03] 1:4 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"86.8","lowerLimit":"82.2","upperLimit":"90.6"}]}]},{"title":"Before Vaccination 1: PMB1256[B03] 1:8 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"11.2","lowerLimit":"7.7","upperLimit":"15.5"}]}]},{"title":"1 month after Vac 3: PMB1256[B03] 1:8 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"86.4","lowerLimit":"81.8","upperLimit":"90.3"}]}]},{"title":"Before Vaccination 1: PMB1256[B03] 1:16 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","lowerLimit":"6.8","upperLimit":"14.3"}]}]},{"title":"1 month after Vac 3: PMB1256[B03] 1:16 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"85.3","lowerLimit":"80.6","upperLimit":"89.3"}]}]},{"title":"Before Vaccination 1: PMB1256[B03] 1:32 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"4.8","upperLimit":"11.4"}]}]},{"title":"1 month after Vac 3: PMB1256[B03] 1:32 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"78.4","lowerLimit":"73.0","upperLimit":"83.1"}]}]},{"title":"Before Vaccination 1: PMB1256[B03] 1:64 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"2.5","upperLimit":"7.9"}]}]},{"title":"1 month after Vac 3: PMB1256[B03] 1:64 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"56.4","lowerLimit":"50.3","upperLimit":"62.4"}]}]},{"title":"Before Vaccination 1: PMB1256[B03] 1:128 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.2","upperLimit":"3.1"}]}]},{"title":"1 month after Vac 3: PMB1256[B03] 1:128 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"30.8","lowerLimit":"25.3","upperLimit":"36.6"}]}]},{"title":"Before Vaccination 1: PMB866[B09] 1:4 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"24.5","lowerLimit":"19.6","upperLimit":"30.1"}]}]},{"title":"1 month after Vac 3: PMB866[B09] 1:4 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"78.5","lowerLimit":"73.1","upperLimit":"83.2"}]}]},{"title":"Before Vaccination 1: PMB866[B09] 1:8 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"23.5","lowerLimit":"18.6","upperLimit":"28.9"}]}]},{"title":"1 month after Vac 3: PMB866[B09] 1:8 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"77.0","lowerLimit":"71.6","upperLimit":"81.9"}]}]},{"title":"Before Vaccination 1: PMB866[B09] 1:16 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"18.8","lowerLimit":"14.3","upperLimit":"23.9"}]}]},{"title":"1 month after Vac 3: PMB866[B09] 1:16 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"73.4","lowerLimit":"67.7","upperLimit":"78.5"}]}]},{"title":"Before Vaccination 1: PMB866[B09] 1:32 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"11.9","lowerLimit":"8.3","upperLimit":"16.3"}]}]},{"title":"1 month after Vac 3: PMB866[B09] 1:32 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"52.6","lowerLimit":"46.5","upperLimit":"58.6"}]}]},{"title":"Before Vaccination 1: PMB866[B09] 1:64 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"4.7","lowerLimit":"2.5","upperLimit":"7.9"}]}]},{"title":"1 month after Vac 3: PMB866[B09] 1:64 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"27.7","lowerLimit":"22.5","upperLimit":"33.4"}]}]},{"title":"Before Vaccination 1: PMB866[B09] 1:128 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"0.2","upperLimit":"3.1"}]}]},{"title":"1 month after Vac 3: PMB866[B09] 1:128 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"12.8","lowerLimit":"9.1","upperLimit":"17.3"}]}]},{"title":"Before Vaccination 1: PMB431[B15] 1:4 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"44.9","lowerLimit":"38.9","upperLimit":"51.0"}]}]},{"title":"1 month after Vac 3: PMB431[B15] 1:4 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"97.1","lowerLimit":"94.4","upperLimit":"98.7"}]}]},{"title":"Before Vaccination 1: PMB431[B15] 1:8 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"43.8","lowerLimit":"37.8","upperLimit":"49.9"}]}]},{"title":"1 month after Vac 3: PMB431[B15] 1:8 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"96.7","lowerLimit":"93.9","upperLimit":"98.5"}]}]},{"title":"Before Vaccination 1: PMB431[B15] 1:16 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"41.2","lowerLimit":"35.4","upperLimit":"47.3"}]}]},{"title":"1 month after Vac 3: PMB431[B15] 1:16 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"96.7","lowerLimit":"93.9","upperLimit":"98.5"}]}]},{"title":"Before Vaccination 1: PMB431[B15] 1:32 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"23.7","lowerLimit":"18.8","upperLimit":"29.2"}]}]},{"title":"1 month after Vac 3: PMB431[B15] 1:32 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"84.4","lowerLimit":"79.6","upperLimit":"88.5"}]}]},{"title":"Before Vaccination 1: PMB431[B15] 1:64 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"5.1","upperLimit":"11.9"}]}]},{"title":"1 month after Vac 3: PMB431[B15] 1:64 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"56.5","lowerLimit":"50.4","upperLimit":"62.5"}]}]},{"title":"Before Vaccination 1: PMB431[B15] 1:128 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"0.4","upperLimit":"3.7"}]}]},{"title":"1 month after Vac 3: PMB431[B15] 1:128 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"22.5","lowerLimit":"17.7","upperLimit":"27.9"}]}]},{"title":"Before Vaccination 1: PMB648[B16] 1:4 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"24.4","lowerLimit":"19.4","upperLimit":"30.0"}]}]},{"title":"1 month after Vac 3: PMB648[B16] 1:4 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"79.1","lowerLimit":"73.8","upperLimit":"83.8"}]}]},{"title":"Before Vaccination 1: PMB648[B16] 1:8 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"21.9","lowerLimit":"17.1","upperLimit":"27.3"}]}]},{"title":"1 month after Vac 3: PMB648[B16] 1:8 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"78.0","lowerLimit":"72.6","upperLimit":"82.8"}]}]},{"title":"Before Vaccination 1: PMB648[B16] 1:16 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"18.9","lowerLimit":"14.4","upperLimit":"24.1"}]}]},{"title":"1 month after Vac 3: PMB648[B16] 1:16 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"76.6","lowerLimit":"71.1","upperLimit":"81.5"}]}]},{"title":"Before Vaccination 1: PMB648[B16] 1:32 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"11.9","lowerLimit":"8.2","upperLimit":"16.3"}]}]},{"title":"1 month after Vac 3: PMB648[B16] 1:32 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"61.2","lowerLimit":"55.1","upperLimit":"67.0"}]}]},{"title":"Before Vaccination 1: PMB648[B16] 1:64 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"7.4","lowerLimit":"4.6","upperLimit":"11.2"}]}]},{"title":"1 month after Vac 3: PMB648[B16] 1:64 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"34.4","lowerLimit":"28.8","upperLimit":"40.4"}]}]},{"title":"Before Vaccination 1: PMB648[B16] 1:128 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"1.9","lowerLimit":"0.6","upperLimit":"4.3"}]}]},{"title":"1 month after Vac 3: PMB648[B16] 1:128 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"16.8","lowerLimit":"12.6","upperLimit":"21.8"}]}]}]},{"type":"SECONDARY","title":"hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, number of participants analyzed signifies participants with valid and determinate hSBA titers for the given strain. Here, N signifies participants with valid and determinate assay results for the given antigen or strain. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"Before first vaccination, 1 month after third vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"300"}]}],"classes":[{"title":"PMB3175[A29]:Before Vaccination 1 (N=280)","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"6.4","upperLimit":"8.0"}]}]},{"title":"PMB3175[A29]:1 Month after Vaccination 3 (N=283)","categories":[{"measurements":[{"groupId":"OG000","value":"96.3","lowerLimit":"86.9","upperLimit":"106.9"}]}]},{"title":"PMB3010[A06]:Before Vaccination 1 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"10.3","lowerLimit":"9.5","upperLimit":"11.2"}]}]},{"title":"PMB3010[A06]:1 Month after Vaccination 3 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"69.9","lowerLimit":"61.8","upperLimit":"79.1"}]}]},{"title":"PMB3040[A07]:Before Vaccination 1 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"13.9","lowerLimit":"12.0","upperLimit":"16.0"}]}]},{"title":"PMB3040[A07]:1 Month after Vaccination 3 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"60.4","lowerLimit":"54.6","upperLimit":"66.8"}]}]},{"title":"PMB824[A12]: Before Vaccination 1 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"8.2","upperLimit":"8.6"}]}]},{"title":"PMB824[A12]:1 Month after Vaccination 3 (N=275)","categories":[{"measurements":[{"groupId":"OG000","value":"20.6","lowerLimit":"18.8","upperLimit":"22.6"}]}]},{"title":"PMB1672[A15]:Before Vaccination 1 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"7.1","upperLimit":"9.0"}]}]},{"title":"PMB1672[A15]:1 Month after Vaccination 3 (N=279)","categories":[{"measurements":[{"groupId":"OG000","value":"43.1","lowerLimit":"38.4","upperLimit":"48.4"}]}]},{"title":"PMB1989[A19]:Before Vaccination 1 (N=278)","categories":[{"measurements":[{"groupId":"OG000","value":"12.1","lowerLimit":"11.1","upperLimit":"13.3"}]}]},{"title":"PMB1989[A19]:1 Month after Vaccination 3 (N=284)","categories":[{"measurements":[{"groupId":"OG000","value":"87.3","lowerLimit":"77.7","upperLimit":"98.0"}]}]},{"title":"PMB1256[B03]:Before Vaccination 1 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"5.1","lowerLimit":"4.7","upperLimit":"5.6"}]}]},{"title":"PMB1256[B03]:1 Month after Vaccination 3 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"49.8","lowerLimit":"42.2","upperLimit":"58.7"}]}]},{"title":"PMB866[B09]:Before Vaccination 1 (N=277)","categories":[{"measurements":[{"groupId":"OG000","value":"6.1","lowerLimit":"5.5","upperLimit":"6.7"}]}]},{"title":"PMB866[B09]:1 Month after Vaccination 3 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"23.3","lowerLimit":"19.9","upperLimit":"27.1"}]}]},{"title":"PMB431[B15]:Before Vaccination 1 (N=274)","categories":[{"measurements":[{"groupId":"OG000","value":"9.1","lowerLimit":"8.1","upperLimit":"10.3"}]}]},{"title":"PMB431[B15]:1 Month after Vaccination 3 (N=276)","categories":[{"measurements":[{"groupId":"OG000","value":"49.4","lowerLimit":"44.6","upperLimit":"54.8"}]}]},{"title":"PMB648[B16]:Before Vaccination 1 (N=270)","categories":[{"measurements":[{"groupId":"OG000","value":"6.2","lowerLimit":"5.5","upperLimit":"6.9"}]}]},{"title":"PMB648[B16]:1 Month after Vaccination 3 (N=273)","categories":[{"measurements":[{"groupId":"OG000","value":"26.5","lowerLimit":"22.8","upperLimit":"30.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Composite hSBA Titer >=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, N signifies participants valid and determinate hSBA results on all 4 strains at the given time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Before vaccination 1, 1 Month after Vaccination 2","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1723"}]}],"classes":[{"title":"Before First Vaccination (N=1612)","categories":[{"measurements":[{"groupId":"OG000","value":"7.3","lowerLimit":"6.0","upperLimit":"8.6"}]}]},{"title":"1 Month after Vaccination 2 (N=1620)","categories":[{"measurements":[{"groupId":"OG000","value":"64.5","lowerLimit":"62.1","upperLimit":"66.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at both the specified time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"One month after second Bivalent rLP2086 vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1723"}]}],"classes":[{"title":"PMB80[A22] (N=1679)","categories":[{"measurements":[{"groupId":"OG000","value":"66.9","lowerLimit":"64.6","upperLimit":"69.2"}]}]},{"title":"PMB2001[A56] (N=1637)","categories":[{"measurements":[{"groupId":"OG000","value":"85.9","lowerLimit":"84.1","upperLimit":"87.5"}]}]},{"title":"PMB2948[B24] (N=1658)","categories":[{"measurements":[{"groupId":"OG000","value":"67.9","lowerLimit":"65.6","upperLimit":"70.2"}]}]},{"title":"PMB2707[B44] (N=1686)","categories":[{"measurements":[{"groupId":"OG000","value":"55.5","lowerLimit":"53.1","upperLimit":"57.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Titers >=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Before Vaccination (Vac) 1, 1 Month after Vac 2, 3","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1723"}]}],"classes":[{"title":"Before Vac 1: PMB80[A22] 1:16 (N=1704)","categories":[{"measurements":[{"groupId":"OG000","value":"33.6","lowerLimit":"31.3","upperLimit":"35.9"}]}]},{"title":"1 month after Vac 2: PMB80[A22] 1:16 (N=1697)","categories":[{"measurements":[{"groupId":"OG000","value":"84.7","lowerLimit":"82.9","upperLimit":"86.4"}]}]},{"title":"1 month after Vac 3: PMB80[A22] 1:16 (N=1714)","categories":[{"measurements":[{"groupId":"OG000","value":"93.5","lowerLimit":"92.2","upperLimit":"94.6"}]}]},{"title":"Before Vac 1: PMB2001[A56] 1:8 (N=1657)","categories":[{"measurements":[{"groupId":"OG000","value":"32.2","lowerLimit":"29.9","upperLimit":"34.5"}]}]},{"title":"1 month after Vac 2: PMB2001[A56] 1:8) (N=1701)","categories":[{"measurements":[{"groupId":"OG000","value":"97.4","lowerLimit":"96.5","upperLimit":"98.1"}]}]},{"title":"1 month after Vac 3: PMB2001[A56] 1:8 (N=1708)","categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"98.9","upperLimit":"99.7"}]}]},{"title":"Before Vac 1: PMB2948[B24] 1:8 (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"33.1","lowerLimit":"30.9","upperLimit":"35.4"}]}]},{"title":"1 month after Vac 2: PMB2948[B24] 1:8 (N=1685)","categories":[{"measurements":[{"groupId":"OG000","value":"86.5","lowerLimit":"84.7","upperLimit":"88.1"}]}]},{"title":"1 month after Vac 3:PMB2948[B24] 1:8 (N=1702)","categories":[{"measurements":[{"groupId":"OG000","value":"95.1","lowerLimit":"93.9","upperLimit":"96.0"}]}]},{"title":"Before Vac 1: PMB2707[B44] 1:8 (N=1716)","categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"9.6","upperLimit":"12.6"}]}]},{"title":"1 month after Vac 2: PMB2707[B44] 1:8 (N=1693)","categories":[{"measurements":[{"groupId":"OG000","value":"68.3","lowerLimit":"66.1","upperLimit":"70.6"}]}]},{"title":"1 month after Vac 3: PMB2707[B44] 1:8 (N=1703)","categories":[{"measurements":[{"groupId":"OG000","value":"87.4","lowerLimit":"85.8","upperLimit":"89.0"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With hSBA Titers >=1:4,>=1:8,>=1:16,>=1:32,>=1:64,>=1:128 for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1","description":"Results for PMB80\\[A22\\] 1:16, PMB2001\\[A56\\] 1:8, PMB2948\\[B24\\] 1:8 and PMB2707\\[B44\\] 1:8 are reported under secondary endpoint 'Percentage of Participants With hSBA Titers \\>=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1'.","populationDescription":"Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Before Vaccination (Vac) 1, 1 Month after Vac 2, 3","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1723"}]}],"classes":[{"title":"Before Vac 1: PMB80[A22] 1:4 (N=1704)","categories":[{"measurements":[{"groupId":"OG000","value":"42.1","lowerLimit":"39.7","upperLimit":"44.5"}]}]},{"title":"1 month after Vac 2: PMB80[A22] 1:4 (N=1697)","categories":[{"measurements":[{"groupId":"OG000","value":"86.2","lowerLimit":"84.5","upperLimit":"87.8"}]}]},{"title":"1 month after Vac 3: PMB80[A22] 1:4 (N=1714)","categories":[{"measurements":[{"groupId":"OG000","value":"94.3","lowerLimit":"93.1","upperLimit":"95.3"}]}]},{"title":"Before Vac 1: PMB80[A22] 1:8 (N=1704)","categories":[{"measurements":[{"groupId":"OG000","value":"38.8","lowerLimit":"36.5","upperLimit":"41.2"}]}]},{"title":"1 month after Vac 2: PMB80[A22] 1:8 (N=1697)","categories":[{"measurements":[{"groupId":"OG000","value":"85.7","lowerLimit":"83.9","upperLimit":"87.3"}]}]},{"title":"1 month after Vac 3: PMB80[A22] 1:8 (N=1714)","categories":[{"measurements":[{"groupId":"OG000","value":"94.1","lowerLimit":"92.9","upperLimit":"95.2"}]}]},{"title":"Before Vac 1: PMB80[A22] 1:32 (N=1704)","categories":[{"measurements":[{"groupId":"OG000","value":"19.7","lowerLimit":"17.8","upperLimit":"21.6"}]}]},{"title":"1 month after Vac 2: PMB80[A22] 1:32 (N=1697)","categories":[{"measurements":[{"groupId":"OG000","value":"71.2","lowerLimit":"69.0","upperLimit":"73.3"}]}]},{"title":"1 month after Vac 3: PMB80[A22] 1:32 (N=1714)","categories":[{"measurements":[{"groupId":"OG000","value":"85.5","lowerLimit":"83.8","upperLimit":"87.2"}]}]},{"title":"Before Vac 1: PMB80[A22] 1:64 (N=1704)","categories":[{"measurements":[{"groupId":"OG000","value":"9.6","lowerLimit":"8.3","upperLimit":"11.1"}]}]},{"title":"1 month after Vac 2: PMB80[A22] 1:64 (N=1697)","categories":[{"measurements":[{"groupId":"OG000","value":"49.9","lowerLimit":"47.4","upperLimit":"52.3"}]}]},{"title":"1 month after Vac 3: PMB80[A22] 1:64 (N=1714)","categories":[{"measurements":[{"groupId":"OG000","value":"64.4","lowerLimit":"62.1","upperLimit":"66.7"}]}]},{"title":"Before Vac 1: PMB80[A22] 1:128 (N=1704)","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.6","upperLimit":"4.4"}]}]},{"title":"1 month after Vac 2: PMB80[A22] 1:128 (N=1697)","categories":[{"measurements":[{"groupId":"OG000","value":"29.9","lowerLimit":"27.8","upperLimit":"32.2"}]}]},{"title":"1 month after Vac 3: PMB80[A22] 1:128 (N=1714)","categories":[{"measurements":[{"groupId":"OG000","value":"41.7","lowerLimit":"39.4","upperLimit":"44.1"}]}]},{"title":"Before Vac 1: PMB2001[A56] 1:4 (N=1657)","categories":[{"measurements":[{"groupId":"OG000","value":"35.9","lowerLimit":"33.6","upperLimit":"38.3"}]}]},{"title":"1 month after Vac 2: PMB2001[A56] 1:4 (N=1701)","categories":[{"measurements":[{"groupId":"OG000","value":"97.8","lowerLimit":"97.0","upperLimit":"98.5"}]}]},{"title":"1 month after Vac 3: PMB2001[A56] 1:4 (N=1708)","categories":[{"measurements":[{"groupId":"OG000","value":"99.4","lowerLimit":"98.9","upperLimit":"99.7"}]}]},{"title":"Before Vac 1: PMB2001[A56] 1:16 (N=1657)","categories":[{"measurements":[{"groupId":"OG000","value":"30.4","lowerLimit":"28.2","upperLimit":"32.7"}]}]},{"title":"1 month after Vac 2: PMB2001[A56] 1:16 (N=1701)","categories":[{"measurements":[{"groupId":"OG000","value":"97.1","lowerLimit":"96.1","upperLimit":"97.8"}]}]},{"title":"1 month after Vac 3: PMB2001[A56] 1:16 (N=1708)","categories":[{"measurements":[{"groupId":"OG000","value":"99.2","lowerLimit":"98.7","upperLimit":"99.6"}]}]},{"title":"Before Vac 1: PMB2001[A56] ] 1:32 (N=1657)","categories":[{"measurements":[{"groupId":"OG000","value":"24.4","lowerLimit":"22.3","upperLimit":"26.5"}]}]},{"title":"1 month after Vac 2: PMB2001[A56] 1:32 (N=1701)","categories":[{"measurements":[{"groupId":"OG000","value":"92.8","lowerLimit":"91.4","upperLimit":"94.0"}]}]},{"title":"1 month after Vac 3: PMB2001[A56] 1:32 (N=1708)","categories":[{"measurements":[{"groupId":"OG000","value":"97.2","lowerLimit":"96.4","upperLimit":"98.0"}]}]},{"title":"Before Vac 1: PMB2001[A56] 1:64 (N=1657)","categories":[{"measurements":[{"groupId":"OG000","value":"16.4","lowerLimit":"14.6","upperLimit":"18.2"}]}]},{"title":"1 month after Vac 2 :PMB2001[A56] 1:64 (N=1701)","categories":[{"measurements":[{"groupId":"OG000","value":"80.8","lowerLimit":"78.9","upperLimit":"82.7"}]}]},{"title":"1 month after Vac 3 :PMB2001[A56] 1:64 (N=1708)","categories":[{"measurements":[{"groupId":"OG000","value":"90.5","lowerLimit":"89.0","upperLimit":"91.9"}]}]},{"title":"Before Vac 1: PMB2001[A56] 1:128 (N=1657)","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"5.9","upperLimit":"8.5"}]}]},{"title":"1 month after Vac 2: PMB2001[A56] 1:128 (N=1701)","categories":[{"measurements":[{"groupId":"OG000","value":"56.6","lowerLimit":"54.2","upperLimit":"58.9"}]}]},{"title":"1 month after Vac 3: PMB2001[A56] 1:128 (N=1708)","categories":[{"measurements":[{"groupId":"OG000","value":"73.7","lowerLimit":"71.5","upperLimit":"75.7"}]}]},{"title":"Before Vac 1: PMB2948[B24] 1:4 (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"35.0","lowerLimit":"32.7","upperLimit":"37.3"}]}]},{"title":"1 month after Vac 2: PMB2948[B24] 1:4 (N=1685)","categories":[{"measurements":[{"groupId":"OG000","value":"87.2","lowerLimit":"85.5","upperLimit":"88.7"}]}]},{"title":"1 month after Vac 3: PMB2948[B24] 1:4 (N=1702)","categories":[{"measurements":[{"groupId":"OG000","value":"95.8","lowerLimit":"94.8","upperLimit":"96.7"}]}]},{"title":"Before Vac 1: PMB2948[B24] 1:16 (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"29.5","lowerLimit":"27.3","upperLimit":"31.7"}]}]},{"title":"1 month after Vac 2: PMB2948[B24] 1:16 (N=1685)","categories":[{"measurements":[{"groupId":"OG000","value":"83.7","lowerLimit":"81.9","upperLimit":"85.5"}]}]},{"title":"1 month after Vac 3: PMB2948[B24] 1:16 (N=1702)","categories":[{"measurements":[{"groupId":"OG000","value":"93.2","lowerLimit":"91.9","upperLimit":"94.3"}]}]},{"title":"Before Vac 1: PMB2948[B24] 1:32 (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"18.1","lowerLimit":"16.3","upperLimit":"20.0"}]}]},{"title":"1 month after Vac 2: PMB2948[B24] 1:32 (N=1685)","categories":[{"measurements":[{"groupId":"OG000","value":"65.6","lowerLimit":"63.3","upperLimit":"67.8"}]}]},{"title":"1 month after Vac 3: PMB2948[B24] 1:32 (N=1702)","categories":[{"measurements":[{"groupId":"OG000","value":"75.1","lowerLimit":"73.0","upperLimit":"77.2"}]}]},{"title":"Before Vac 1: PMB2948[B24] 1:64 (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"8.4","lowerLimit":"7.1","upperLimit":"9.8"}]}]},{"title":"1 month after Vac 2: PMB2948[B24] 1:64 (N=1685)","categories":[{"measurements":[{"groupId":"OG000","value":"40.4","lowerLimit":"38.0","upperLimit":"42.7"}]}]},{"title":"1 month after Vac 3: PMB2948[B24] 1:64 (N=1702)","categories":[{"measurements":[{"groupId":"OG000","value":"48.8","lowerLimit":"46.4","upperLimit":"51.2"}]}]},{"title":"Before Vac 1: PMB2948[B24] 1:128 (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"3.3","lowerLimit":"2.5","upperLimit":"4.3"}]}]},{"title":"1 month after Vac 2: PMB2948[B24] 1:128 (N=1685)","categories":[{"measurements":[{"groupId":"OG000","value":"22.8","lowerLimit":"20.9","upperLimit":"24.9"}]}]},{"title":"1 month after Vac 3: PMB2948[B24] 1:128 (N=1702)","categories":[{"measurements":[{"groupId":"OG000","value":"27.8","lowerLimit":"25.7","upperLimit":"30.0"}]}]},{"title":"Before Vac 1: PMB2707[B44] 1:4 (N=1716)","categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"12.8","upperLimit":"16.2"}]}]},{"title":"1 month after Vac 2: PMB2707[B44] 1:4 (N=1693)","categories":[{"measurements":[{"groupId":"OG000","value":"71.5","lowerLimit":"69.3","upperLimit":"73.7"}]}]},{"title":"1 month after Vac 3: PMB2707[B44] 1:4 (N=1703)","categories":[{"measurements":[{"groupId":"OG000","value":"89.7","lowerLimit":"88.1","upperLimit":"91.1"}]}]},{"title":"Before Vac 1: PMB2707[B44] 1:16 (N=1716)","categories":[{"measurements":[{"groupId":"OG000","value":"7.8","lowerLimit":"6.5","upperLimit":"9.1"}]}]},{"title":"1 month after Vac 2: PMB2707[B44] 1:16 (N=1693)","categories":[{"measurements":[{"groupId":"OG000","value":"61.0","lowerLimit":"58.6","upperLimit":"63.3"}]}]},{"title":"1 month after Vac 3: PMB2707[B44] 1:16 (N=1703)","categories":[{"measurements":[{"groupId":"OG000","value":"83.3","lowerLimit":"81.4","upperLimit":"85.0"}]}]},{"title":"Before Vac 1: PMB2707[B44] 1:32 (N=1716)","categories":[{"measurements":[{"groupId":"OG000","value":"4.3","lowerLimit":"3.4","upperLimit":"5.4"}]}]},{"title":"1 month after Vac 2: PMB2707[B44] 1:32 (N=1693)","categories":[{"measurements":[{"groupId":"OG000","value":"41.9","lowerLimit":"39.6","upperLimit":"44.3"}]}]},{"title":"1 month after Vac 3: PMB2707[B44] 1:32 (N=1703)","categories":[{"measurements":[{"groupId":"OG000","value":"67.1","lowerLimit":"64.8","upperLimit":"69.3"}]}]},{"title":"Before Vac 1: PMB2707[B44] 1:64 (N=1716)","categories":[{"measurements":[{"groupId":"OG000","value":"2.3","lowerLimit":"1.6","upperLimit":"3.1"}]}]},{"title":"1 month after Vac 2: PMB2707[B44] 1:64 (N=1693)","categories":[{"measurements":[{"groupId":"OG000","value":"30.3","lowerLimit":"28.1","upperLimit":"32.6"}]}]},{"title":"1 month after Vac 3: PMB2707[B44] 1:64 (N=1703)","categories":[{"measurements":[{"groupId":"OG000","value":"49.8","lowerLimit":"47.4","upperLimit":"52.2"}]}]},{"title":"Before Vac 1: PMB2707[B44] 1:128 (N=1716)","categories":[{"measurements":[{"groupId":"OG000","value":"0.8","lowerLimit":"0.4","upperLimit":"1.3"}]}]},{"title":"1 month after Vac 2: PMB2707[B44] 1:128 (N=1693)","categories":[{"measurements":[{"groupId":"OG000","value":"21.0","lowerLimit":"19.1","upperLimit":"23.0"}]}]},{"title":"1 month after Vac 3: PMB2707[B44] 1:128 (N=1703)","categories":[{"measurements":[{"groupId":"OG000","value":"32.1","lowerLimit":"29.9","upperLimit":"34.4"}]}]}]},{"type":"SECONDARY","title":"hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titer","timeFrame":"Before Vaccination (Vac) 1, 1 Month after Vac 2, 3","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1723"}]}],"classes":[{"title":"PMB80[A22]: Before Vac 1 (N=1704)","categories":[{"measurements":[{"groupId":"OG000","value":"12.8","lowerLimit":"12.3","upperLimit":"13.3"}]}]},{"title":"PMB80[A22]: 1 Month after Vac 2 (N=1697)","categories":[{"measurements":[{"groupId":"OG000","value":"49.0","lowerLimit":"46.2","upperLimit":"52.1"}]}]},{"title":"PMB80[A22]: 1 Month after Vac 3 (N=1714)","categories":[{"measurements":[{"groupId":"OG000","value":"74.3","lowerLimit":"70.2","upperLimit":"78.6"}]}]},{"title":"PMB2001[A56]: Before Vac 1 (N=1657)","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","lowerLimit":"8.3","upperLimit":"9.3"}]}]},{"title":"PMB2001[A56]: 1 Month after Vac 2 (N=1701)","categories":[{"measurements":[{"groupId":"OG000","value":"114.3","lowerLimit":"107.9","upperLimit":"121.0"}]}]},{"title":"PMB2001[A56]: 1 Month after Vac 3 (N=1708)","categories":[{"measurements":[{"groupId":"OG000","value":"176.7","lowerLimit":"167.8","upperLimit":"186.1"}]}]},{"title":"PMB2948[B24]: Before Vac 1 (N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"7.3","upperLimit":"8.0"}]}]},{"title":"PMB2948[B24]: 1 Month after Vac 2 (N=1685)","categories":[{"measurements":[{"groupId":"OG000","value":"35.8","lowerLimit":"33.7","upperLimit":"38.2"}]}]},{"title":"PMB2948[B24]: 1 Month after Vac 3 (N=1702)","categories":[{"measurements":[{"groupId":"OG000","value":"49.5","lowerLimit":"46.8","upperLimit":"52.4"}]}]},{"title":"PMB2707[B44]: Before Vac 1 (N=1716)","categories":[{"measurements":[{"groupId":"OG000","value":"4.8","lowerLimit":"4.7","upperLimit":"4.9"}]}]},{"title":"PMB2707[B44]: 1 Month after Vac 2 (N=1693)","categories":[{"measurements":[{"groupId":"OG000","value":"22.6","lowerLimit":"20.9","upperLimit":"24.4"}]}]},{"title":"PMB2707[B44]: 1 Month after Vac 3 (N=1703)","categories":[{"measurements":[{"groupId":"OG000","value":"47.6","lowerLimit":"44.2","upperLimit":"51.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination","populationDescription":"Data was not reported because 3-fold rise analyses was not performed as per change in planned analysis.","reportingStatus":"POSTED","timeFrame":"One month after third bivalent rLP2086 vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination: Group 1","populationDescription":"Evaluable immunogenicity population. Here, N signifies participants with valid and determinate hSBA titers for the given strain at the specified time point. This outcome measure was planned to be analyzed for Group 1 only.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"One month after third bivalent rLP2086 vaccination","groups":[{"id":"OG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1723"}]}],"classes":[{"title":"PMB80[A22]: 1 Month after Vac 3 (N=1695)","categories":[{"measurements":[{"groupId":"OG000","value":"89.0","lowerLimit":"87.4","upperLimit":"90.4"}]}]},{"title":"PMB2001[A56]: 1 Month after Vac 3 (N=1642)","categories":[{"measurements":[{"groupId":"OG000","value":"95.3","lowerLimit":"94.2","upperLimit":"96.3"}]}]},{"title":"PMB2948[B24]: 1 Month after Vac 3 (N=1675)","categories":[{"measurements":[{"groupId":"OG000","value":"87.1","lowerLimit":"85.4","upperLimit":"88.7"}]}]},{"title":"PMB2707[B44]: 1 Month after Vac 3(N=1696)","categories":[{"measurements":[{"groupId":"OG000","value":"81.8","lowerLimit":"79.9","upperLimit":"83.6"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"1","timeFrame":"AEs/SAEs: recorded from first vaccination through 6 months after third vaccination. Participants recorded pre-specified reactogenicity events (local reactions, systemic events) in electronic diary within 7 days after first, second and third vaccination","description":"All AEs collected on case report form are shown below as having been collected via non-systematic assessment. All events reported via electronic diary (reactogenicity events) are shown below as having been collected via systematic assessment. Reactogenicity events are grouped by all severities and doses combined.","eventGroups":[{"id":"EG000","title":"Group 1 rLP2086","description":"Recombinant lipoprotein 2086 (rLP2086) vaccine on a 0-, 2-, 6- month schedule.","seriousNumAffected":33,"seriousNumAtRisk":2471,"otherNumAffected":2193,"otherNumAtRisk":2471},{"id":"EG001","title":"Group 2 Saline","description":"Saline on a 0-, 2-, 6- month schedule.","seriousNumAffected":11,"seriousNumAtRisk":822,"otherNumAffected":567,"otherNumAtRisk":822}],"seriousEvents":[{"term":"Sudden hearing loss","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Mastoiditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Otosalpingitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Pyelonephritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Road traffic accident","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Craniocerebral injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Laceration","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Tendon injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Intervertebral disc protrusion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":2,"numAtRisk":822}]},{"term":"Benign intracranial hypertension","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Dystonia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Multiple sclerosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Abortion missed","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Ectopic pregnancy","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Hyperemesis gravidarum","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Dissociative disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Eating disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":2471},{"groupId":"EG001","numAffected":1,"numAtRisk":822}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":2471},{"groupId":"EG001","numAffected":0,"numAtRisk":822}]}],"otherEvents":[{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":2471},{"groupId":"EG001","numAffected":6,"numAtRisk":822}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":2471},{"groupId":"EG001","numAffected":10,"numAtRisk":822}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":98,"numAtRisk":2471},{"groupId":"EG001","numAffected":29,"numAtRisk":822}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":77,"numAtRisk":2471},{"groupId":"EG001","numAffected":33,"numAtRisk":822}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":45,"numAtRisk":2471},{"groupId":"EG001","numAffected":10,"numAtRisk":822}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":2471},{"groupId":"EG001","numAffected":10,"numAtRisk":822}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":2471},{"groupId":"EG001","numAffected":12,"numAtRisk":822}]},{"term":"Tonsillitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":2471},{"groupId":"EG001","numAffected":11,"numAtRisk":822}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":2471},{"groupId":"EG001","numAffected":10,"numAtRisk":822}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":31,"numAtRisk":2471},{"groupId":"EG001","numAffected":6,"numAtRisk":822}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":2471},{"groupId":"EG001","numAffected":11,"numAtRisk":822}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":55,"numAtRisk":2471},{"groupId":"EG001","numAffected":10,"numAtRisk":822}]},{"term":"Pain at injection site - Any (reactogenicity event)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"Local Reactions","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2184,"numAtRisk":2438},{"groupId":"EG001","numAffected":147,"numAtRisk":808}]},{"term":"Redness -Any (reactogenicity event)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"Local Reactions","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":537,"numAtRisk":2438},{"groupId":"EG001","numAffected":8,"numAtRisk":808}]},{"term":"Swelling -Any (reactogenicity event)","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"Local Reactions","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":612,"numAtRisk":2438},{"groupId":"EG001","numAffected":8,"numAtRisk":808}]},{"term":"Fever >=38.0 degrees C -Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":108,"numAtRisk":2432},{"groupId":"EG001","numAffected":14,"numAtRisk":807}]},{"term":"Vomiting - Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":130,"numAtRisk":2438},{"groupId":"EG001","numAffected":37,"numAtRisk":808}]},{"term":"Diarrhea-Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":497,"numAtRisk":2438},{"groupId":"EG001","numAffected":158,"numAtRisk":808}]},{"term":"Headache - Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1440,"numAtRisk":2438},{"groupId":"EG001","numAffected":391,"numAtRisk":808}]},{"term":"Fatigue -Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1576,"numAtRisk":2438},{"groupId":"EG001","numAffected":411,"numAtRisk":808}]},{"term":"Chills - Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":697,"numAtRisk":2438},{"groupId":"EG001","numAffected":133,"numAtRisk":808}]},{"term":"Muscle pain -Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":916,"numAtRisk":2438},{"groupId":"EG001","numAffected":170,"numAtRisk":808}]},{"term":"Joint pain -Any (reactogenicity event)","organSystem":"General disorders","sourceVocabulary":"Systemic Events","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":723,"numAtRisk":2438},{"groupId":"EG001","numAffected":136,"numAtRisk":808}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Restriction Description: Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"interventionBrowseModule":{"meshes":[{"id":"C484699","term":"factor H-binding protein, Neisseria meningitidis"}]}},"hasResults":true}